Role of duration of diuretic effect in preventing sodium retention

被引:27
作者
Ferguson, JA [1 ]
Sundblad, KJ [1 ]
Becker, PK [1 ]
Gorski, JC [1 ]
Rudy, DW [1 ]
Brater, DC [1 ]
机构
[1] INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN
关键词
D O I
10.1016/S0009-9236(97)90069-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To determine whether the duration of diuretic effect at the active nephron site enhances ability to excrete an exogenous salt toad. Methods: We conducted a study that involved eight patients with New York Heart Association class II to III congestive heart failure. In a randomized, crossover manner, each patient received 3.25 mg intravenous bumetanide at 0 hours and again at 6 hours or a loading dose of 0.5 mg bumetanide at 0 hours followed by a continuous infusion of 0.5 mg/hr for 6 hours. Response was followed for 12 hours; a total of 6.5 mg of bumetanide was administered in each arm of the study. Eight hours after dosing began, we administered approximately 80 mEq sodium intravenously and examined its excretion over 4 hours. Results: The percentage of the load excreted was 86% +/- 15% versus 29% +/- 30% for the infusion and bolus regimens, respectively (p = 0.0005). More bumetanide was excreted during the infusion (667 +/- 133 mu g versus 240 +/- 121 mu g; p = 0.0002). During the infusion, however, more sodium was excreted relative to amounts of bumetanide, indicating that the efficiency of response was greater during the infusion, 0.10 +/- 0.02 mEq sodium per microgram bumetanide versus 0.07 +/- 0.05 mEq for the bolus (p = 0.0145). Conclusions: These data support the notions that a long-acting loop diuretic maintains its efficacy and that a longer duration of action facilitates excretion of a sodium load, such as that which might occur during dietary indiscretion.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 23 条
  • [11] HAMMARLUND MM, 1985, J PHARMACOL EXP THER, V233, P447
  • [12] FUROSEMIDE PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTH AND DISEASE - AN UPDATE
    HAMMARLUNDUDENAES, M
    BENET, LZ
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1989, 17 (01): : 1 - 46
  • [13] Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure
    Kramer, WG
    Smith, WB
    Ferguson, J
    Serpas, T
    Grant, AG
    Black, PK
    Brater, DC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (03) : 265 - 270
  • [14] POSTOPERATIVE ENHANCEMENT OF URINARY OUTPUT IN PATIENTS WITH ACUTE-RENAL-FAILURE USING CONTINUOUS FUROSEMIDE THERAPY
    KRASNA, MJ
    SCOTT, GE
    SCHOLZ, PM
    SPOTNITZ, AJ
    MACKENZIE, JW
    PENN, F
    [J]. CHEST, 1986, 89 (02) : 294 - 295
  • [15] INTERMITTENT ADMINISTRATION OF FUROSEMIDE VS CONTINUOUS INFUSION PRECEDED BY A LOADING DOSE FOR CONGESTIVE-HEART-FAILURE
    LAHAV, M
    REGEV, A
    RAANANI, P
    THEODOR, E
    [J]. CHEST, 1992, 102 (03) : 725 - 731
  • [16] LOOP DIURETICS FOR CHRONIC RENAL-INSUFFICIENCY - A CONTINUOUS INFUSION IS MORE EFFICACIOUS THAN BOLUS THERAPY
    RUDY, DW
    VOELKER, JR
    GREENE, PK
    ESPARZA, FA
    BRATER, DC
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) : 360 - 366
  • [17] BIOAVAILABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TORSEMIDE IN PATIENTS WITH CIRRHOSIS
    SCHWARTZ, S
    BRATER, DC
    POUND, D
    GREEN, PK
    KRAMER, WG
    RUDY, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (01) : 90 - 97
  • [18] DIURETIC EFFICIENCY OF FUROSEMIDE DURING CONTINUOUS ADMINISTRATION VERSUS BOLUS INJECTION IN HEALTHY-VOLUNTEERS
    VANMEYEL, JJM
    SMITS, P
    RUSSEL, FGM
    GERLAG, PGG
    TAN, Y
    GRIBNAU, FWJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 440 - 444
  • [19] VANMEYEL JJM, 1994, J INTERN MED, V235, P329
  • [20] THE PHARMACODYNAMICS OF TORSEMIDE IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
    VARGO, D
    KRAMER, WG
    BLACK, PK
    SMITH, WB
    SERPAS, T
    BRATER, DC
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) : 48 - 54